Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Susan A. Shorter, Alexander S. Gollings, Monique A. M. Gorringe-Pattrick, J. Emma Coakley, Paul D. R. Dyer & Simon C. W. Richardson. (2017) The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery. Expert Opinion on Drug Delivery 14:5, pages 685-696.
Read now
Read now
H Miles Prince & Kate M Newland. (2014)
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs 2:6, pages 625-634.
Read now
Read now
Xiaoying Chen, Jennica L Zaro & Wei-Chiang Shen. (2012) Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opinion on Drug Metabolism & Toxicology 8:5, pages 581-595.
Read now
Read now
Arthur Frankel, Jen-Sing Liu, David Rizzieri & Donna Hogge. (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukemia & Lymphoma 49:3, pages 543-553.
Read now
Read now
Articles from other publishers (34)
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
489
540
.
Mohamad Najarasl, Mehdi Zeinoddini, Ali Reza Saeeidinia & Reza Hasan Sajedi. (2021) The co-expression of denileukin diftitox immunotoxin with Artemin: soluble and aggregation analysis in presence of an efficient protein chaperone. Biologia 76:11, pages 3421-3428.
Crossref
Crossref
Alex Bunker & Tomasz Róg. (2020) Mechanistic Understanding From Molecular Dynamics Simulation in Pharmaceutical Research 1: Drug Delivery. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Seong Guk Park, Bongseo Choi, Yoonji Bae, Yu Geon Lee, Soo Ah Park, Young Chan Chae & Sebyung Kang. (2020) Selective and Effective Cancer Treatments using Target‐Switchable Intracellular Bacterial Toxin Delivery Systems. Advanced Therapeutics 3:9.
Crossref
Crossref
Felix Oh, Jaime F. Modiano, Veronika Bachanova & Daniel A. Vallera. (2020) Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors. Biomolecules 10:6, pages 956.
Crossref
Crossref
Joachim J. Hug, Daniel Krug & Rolf Müller. (2020) Bacteria as genetically programmable producers of bioactive natural products. Nature Reviews Chemistry 4:4, pages 172-193.
Crossref
Crossref
Ajay Kumar Sahi, Pooja Verma, Pallawi, Kameshwarnath Singh & Sanjeev Kumar Mahto. 2019. Biomedical Engineering and its Applications in Healthcare. Biomedical Engineering and its Applications in Healthcare
681
700
.
K.Y. Manoilov. (2018) BIOLOGICAL PROPERTIES AND MEDICAL APPLICATION OF DIPHTHERIA TOXIN DERIVATIVES. Biotechnologia Acta 11:3, pages 27-46.
Crossref
Crossref
Aleksander Rust, Lynda Partridge, Bazbek Davletov & Guillaume Hautbergue. (2017) The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations. Toxins 9:11, pages 344.
Crossref
Crossref
Alexey Ladokhin, Mauricio Vargas-Uribe, Mykola Rodnin, Chiranjib Ghatak & Onkar Sharma. (2017) Cellular Entry of the Diphtheria Toxin Does Not Require the Formation of the Open-Channel State by Its Translocation Domain. Toxins 9:10, pages 299.
Crossref
Crossref
Kaoru Uchimaru. 2017. Adult T-cell Leukemia/Lymphoma. Adult T-cell Leukemia/Lymphoma
67
81
.
Matthew Trendowski. (2015) Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs 75:17, pages 1993-2016.
Crossref
Crossref
Alfred P. See, Jonathon J. Parker & Allen Waziri. (2015) The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression. Journal of Neuro-Oncology 123:3, pages 405-412.
Crossref
Crossref
Victoria Doldán-Martelli & David G. Míguez. (2015) Synergistic Interaction between Selective Drugs in Cell Populations Models. PLOS ONE 10:2, pages e0117558.
Crossref
Crossref
Shirin Karimi, Subhasis Chattopadhyay & Nitya G. Chakraborty. (2015) Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. Immunology 144:2, pages 186-196.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
561
593
.
Brian A. Baldo & Mauro Pagani. (2014) Adverse Events to Nontargeted and Targeted Chemotherapeutic Agents. Immunology and Allergy Clinics of North America 34:3, pages 565-596.
Crossref
Crossref
Ron D. Jachimowicz, Sven Borchmann & Achim Rothe. (2014) Multi-Specific Antibodies for Cancer Immunotherapy. BioDrugs 28:4, pages 331-343.
Crossref
Crossref
Brian A. Baldo & Nghia H. Pham. (2013) Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer and Metastasis Reviews 32:3-4, pages 723-761.
Crossref
Crossref
Alexey Ladokhin. (2013) pH-Triggered Conformational Switching along the Membrane Insertion Pathway of the Diphtheria Toxin T-Domain. Toxins 5:8, pages 1362-1380.
Crossref
Crossref
Monika Słomińska-Wojewódzka & Kirsten Sandvig. (2013) Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro. Antibodies 2:4, pages 236-269.
Crossref
Crossref
V Doldán‐Martelli, R Guantes & DG Míguez. (2013) A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies. CPT: Pharmacometrics & Systems Pharmacology 2:2, pages 1-8.
Crossref
Crossref
Joycelyn Entwistle, Mark Kowalski, Jennifer Brown, Jeannick Cizeau & Glen C. MacDonald. 2013. Antibody-Drug Conjugates and Immunotoxins. Antibody-Drug Conjugates and Immunotoxins
349
367
.
Navdeep Kaur, Karthikeyan Subramani & Yashwant Pathak. 2012. Antibody‐Mediated Drug Delivery Systems. Antibody‐Mediated Drug Delivery Systems
1
12
.
Inna Grodzovski, Michal Lichtenstein, Hanan Galski & Haya Lorberboum‐Galski. (2011) IL‐2‐granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3‐independent apoptotic pathway. International Journal of Cancer 128:8, pages 1966-1980.
Crossref
Crossref
Adrian Bot. 2011. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures
237
244
.
Craig P. Carden, Hendrik-Tobias Arkenau & Johann S. de Bono. 2011. Principles of Anticancer Drug Development. Principles of Anticancer Drug Development
535
567
.
Stephen C. Alley, Dennis Benjamin & Che‐Leung Law. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies
821
855
.
Mohamed A. Shaker & Husam M. Younes. (2009) Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy. Journal of Pharmaceutical Sciences 98:7, pages 2268-2298.
Crossref
Crossref
Madeleine DuvicRakhshandra Talpur. (2008)
Optimizing denileukin diftitox (Ontak
®
) therapy
. Future Oncology 4:4, pages 457-469.
Crossref
Crossref
Windy Dean-Colomb & Francisco J. Esteva. (2008) Emerging Agents in the Treatment of Anthracycline- and Taxane-Refractory Metastatic Breast Cancer. Seminars in Oncology 35, pages S31-S38.
Crossref
Crossref
Shai White-Gilbertson, Semyon Rubinchik & Christina Voelkel-Johnson. (2008) Transformation, translation and TRAIL: An unexpected intersection. Cytokine & Growth Factor Reviews 19:2, pages 167-172.
Crossref
Crossref
Nicole M. Agostino, Arjumand Ali, Suresh G. Nair & Paul J. Mosca. (2007) Current Immunotherapeutic Strategies in Malignant Melanoma. Surgical Oncology Clinics of North America 16:4, pages 945-973.
Crossref
Crossref
Eva Kimby. (2007) Management of advanced-stage peripheral T-cell lymphomas. Current Hematologic Malignancy Reports 2:4, pages 242-248.
Crossref
Crossref